Overview
RANI market data
Price History
RANI price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.45 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.75 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.44 – $3.87 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $111.7 · P/B 4.97 · P/S 35.25.
Company News
Rani Therapeutics Reports Initial Phase 1 Data Showing Oral RT‑114 Delivered Systemic Exposure Exceeding Matched Subcutaneous Administration, With Safety And Tolerability Consistent With GLP‑1/GLP‑2 Agonist ClassBenzinga · Jul 15, 2026, 12:04 PM
Rani Therapeutics Partners With PegBio To Mull Delivery Of Multiple Novel Candidates From PegBio's Obesity And Metabolic Disease Pipeline Through RaniPill PlatformBenzinga · Jul 9, 2026, 8:10 PM
8-K filing — Rani Therapeutics Holdings, Inc. (RANI)SEC EDGAR · Jun 29, 2026, 10:54 PM
Rani Therapeutics Appoints Nicholas Maestas As CFO; Succeeds Svai SanfordBenzinga · Jun 29, 2026, 12:10 PM
Rani Therapeutics shares are trading lower after the company priced a $20 million registered direct offering.Benzinga · May 26, 2026, 4:43 PM
Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq RulesGlobenewswire Inc · May 26, 2026, 12:15 PM
Rani Therapeutics Prices ~$20M Offering Of 12.48M Common Shares At $1.07/ShareBenzinga · May 26, 2026, 12:04 PM
Rani Therapeutics CFO Svai Sanford To Depart From Company After Successor FoundBenzinga · May 15, 2026, 8:10 PM
Rani Therapeutics Hldgs Q1 EPS $(0.04), Inline, Sales $1.708M Beat $500.000K EstimateBenzinga · May 15, 2026, 8:07 PM